MX349514B - Agentes de reversion anticoagulante. - Google Patents

Agentes de reversion anticoagulante.

Info

Publication number
MX349514B
MX349514B MX2014006349A MX2014006349A MX349514B MX 349514 B MX349514 B MX 349514B MX 2014006349 A MX2014006349 A MX 2014006349A MX 2014006349 A MX2014006349 A MX 2014006349A MX 349514 B MX349514 B MX 349514B
Authority
MX
Mexico
Prior art keywords
compounds
reversal agents
anticoagulant
anticoagulant reversal
methods
Prior art date
Application number
MX2014006349A
Other languages
English (en)
Other versions
MX2014006349A (es
Inventor
S Steiner Solomon
E Laulicht Bryan
H Bakhru Sasha
Mathiowitz Edith
Original Assignee
Perosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perosphere Inc filed Critical Perosphere Inc
Publication of MX2014006349A publication Critical patent/MX2014006349A/es
Publication of MX349514B publication Critical patent/MX349514B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Abstract

Se describen compuestos de reversión de anticoagulantes novedosos, así como también métodos para fabricar los compuestos, composiciones farmacéuticas que incluyen los compuestos, métodos para utilizar los compuestos para revertir los efectos anticoagulantes de los inhibidores de la coagulación y ensayos de diagnóstico que comprende los compuestos.
MX2014006349A 2011-11-29 2012-11-29 Agentes de reversion anticoagulante. MX349514B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US201261666291P 2012-06-29 2012-06-29
PCT/US2012/066938 WO2013082210A1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents

Publications (2)

Publication Number Publication Date
MX2014006349A MX2014006349A (es) 2014-09-04
MX349514B true MX349514B (es) 2017-08-02

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006349A MX349514B (es) 2011-11-29 2012-11-29 Agentes de reversion anticoagulante.

Country Status (35)

Country Link
US (4) US9522892B2 (es)
EP (1) EP2785700B1 (es)
JP (1) JP6134731B2 (es)
KR (1) KR101892330B1 (es)
CN (1) CN104080772B (es)
AP (1) AP2014007662A0 (es)
AR (1) AR089020A1 (es)
AU (1) AU2012345975B2 (es)
BR (1) BR112014012892B1 (es)
CA (1) CA2856540C (es)
CL (1) CL2014001399A1 (es)
CO (1) CO6990738A2 (es)
CR (1) CR20140310A (es)
CY (1) CY1117414T1 (es)
DK (1) DK2785700T3 (es)
EA (1) EA027603B1 (es)
EC (1) ECSP14006696A (es)
ES (1) ES2569674T3 (es)
HK (1) HK1202858A1 (es)
HR (1) HRP20160513T1 (es)
HU (1) HUE027452T2 (es)
IL (1) IL232788B (es)
ME (1) ME02424B (es)
MX (1) MX349514B (es)
PE (1) PE20141295A1 (es)
PH (1) PH12014501176B1 (es)
PL (1) PL2785700T3 (es)
PT (1) PT2785700E (es)
RS (1) RS54738B1 (es)
SG (1) SG11201402713WA (es)
SI (1) SI2785700T1 (es)
SM (1) SMT201600161B (es)
UA (1) UA116336C2 (es)
WO (1) WO2013082210A1 (es)
ZA (1) ZA201404793B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069844A1 (en) * 2013-11-08 2015-05-14 Perosphere Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
AU2018365257B2 (en) * 2017-11-13 2021-05-13 Maximum Fidelity Surgical Simulations, LLC Reconstitution of post mortem circulation, specialized methods and procedures
JP2021529765A (ja) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａｘｌ／ｍｅｒ阻害剤の製剤
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
SI20115A (sl) * 1997-04-07 2000-06-30 Axys Pharmaceuticals, Inc. Spojine in sestavki za zdravljenje bolezni, povezanih z aktivnostjo serinskih proteaz, zlasti triptaze
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
CN1152023C (zh) 1999-05-19 2004-06-02 法玛西雅公司 作为抗凝血剂的取代的多环芳基与杂芳基尿嘧啶
CA2412345A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
JP2004501077A (ja) 2000-04-17 2004-01-15 ファルマシア・コーポレーション 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換１，４−キノン
WO2002002519A2 (en) * 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company THROMBIN OR FACTOR Xa INHIBITORS
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
JP2005529860A (ja) 2002-03-27 2005-10-06 グラクソ　グループ　リミテッド ジアミノ酸−アミノ酸−ポリアミンに基づいたジェミニ界面活性剤化合物
EP1550455A1 (en) * 2002-05-23 2005-07-06 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
MA34978B1 (fr) 2011-03-30 2014-03-01 Boehringer Ingelheim Int Antidotes pour anticoagulants

Also Published As

Publication number Publication date
US20170056396A1 (en) 2017-03-02
PT2785700E (pt) 2016-06-02
AU2012345975A1 (en) 2014-05-29
RS54738B1 (sr) 2016-10-31
CO6990738A2 (es) 2014-07-10
HK1202858A1 (en) 2015-10-09
ZA201404793B (en) 2015-04-29
SI2785700T1 (sl) 2016-09-30
JP2014534270A (ja) 2014-12-18
CL2014001399A1 (es) 2014-11-03
NZ625337A (en) 2016-11-25
BR112014012892A2 (pt) 2017-06-13
ES2569674T3 (es) 2016-05-12
CY1117414T1 (el) 2017-04-26
BR112014012892A8 (pt) 2021-06-08
IL232788B (en) 2018-05-31
US9877961B2 (en) 2018-01-30
EA027603B1 (ru) 2017-08-31
MX2014006349A (es) 2014-09-04
SG11201402713WA (en) 2014-06-27
AP2014007662A0 (en) 2014-05-31
AR089020A1 (es) 2014-07-23
CN104080772A (zh) 2014-10-01
PE20141295A1 (es) 2014-10-01
KR20140107259A (ko) 2014-09-04
CA2856540C (en) 2018-04-03
SMT201600161B (it) 2016-07-01
CR20140310A (es) 2014-08-20
PH12014501176A1 (en) 2014-09-01
DK2785700T3 (en) 2016-06-13
HUE027452T2 (en) 2016-09-28
US9522892B2 (en) 2016-12-20
BR112014012892B1 (pt) 2022-12-20
PH12014501176B1 (en) 2014-09-01
CN104080772B (zh) 2016-10-05
US20130137702A1 (en) 2013-05-30
JP6134731B2 (ja) 2017-05-24
CA2856540A1 (en) 2013-06-06
US20210169874A1 (en) 2021-06-10
WO2013082210A1 (en) 2013-06-06
EP2785700A1 (en) 2014-10-08
PL2785700T3 (pl) 2016-09-30
AU2012345975B2 (en) 2016-12-15
ME02424B (me) 2016-09-20
HRP20160513T1 (hr) 2016-07-15
UA116336C2 (uk) 2018-03-12
ECSP14006696A (es) 2015-06-30
IL232788A0 (en) 2014-08-03
EA201490823A1 (ru) 2015-01-30
US20180207152A1 (en) 2018-07-26
KR101892330B1 (ko) 2018-08-27
EP2785700B1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
EA201400579A1 (ru) Антитела к il-36r
EA201201357A1 (ru) Антитела к cd40
EA201590534A1 (ru) Новые бициклические производные
EA201270254A1 (ru) Производные 5-фторпиримидинона
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
NZ743274A (en) Substituted tricyclic compounds as fgfr inhibitors
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201591527A1 (ru) Новые производные пиридина
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201590887A1 (ru) Композиция
EA201370018A1 (ru) Составы рифаксимина и их применение
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
EA201401204A1 (ru) Антитела к il-23p19
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201691044A1 (ru) Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
PH12014501176A1 (en) Anticoagulant reversal agents
EA201490846A1 (ru) Новые производные арилхинолина
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EA201490037A1 (ru) Антагонисты trpv4

Legal Events

Date Code Title Description
FG Grant or registration